{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:06:22Z","timestamp":1760709982800,"version":"3.44.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.pcad.2019.08.001","type":"journal-article","created":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T01:32:19Z","timestamp":1565400739000},"page":"364-369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes"],"prefix":"10.1016","volume":"62","author":[{"given":"James H.","family":"O'Keefe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Nassif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa L.","family":"Magwire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan L.","family":"O'Keefe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.pcad.2019.08.001_bb0005","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.mayocp.2018.07.018","article-title":"Glucose-lowering therapies for cardiovascular risk reduction in type 2 diabetes mellitus: state-of-the-art review","volume":"93","author":"Carbone","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pcad.2019.08.001_bb0010","unstructured":"Services USDoHH. CDC's Division of Diabetes Translation - Data and Statistics - https:\/\/www.cdc.gov\/diabetes\/data\/. In: Prevention CfDCa, ed. Atlanta, Georgia; 2019."},{"issue":"19","key":"10.1016\/j.pcad.2019.08.001_bb0015","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1001\/jama.2019.3471","article-title":"Resurgence in diabetes-related complications","volume":"321","author":"Gregg","year":"2019","journal-title":"JAMA."},{"issue":"20","key":"10.1016\/j.pcad.2019.08.001_bb0020","first-page":"2053","article-title":"Increase in diabetes cases among young people","volume":"317","author":"Abbasi","year":"2017","journal-title":"JAMA."},{"issue":"22","key":"10.1016\/j.pcad.2019.08.001_bb0025","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pcad.2019.08.001_bb0030","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin cardiovascular assessment study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation."},{"issue":"7","key":"10.1016\/j.pcad.2019.08.001_bb0035","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pcad.2019.08.001_bb0040","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pcad.2019.08.001_bb0045","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation."},{"issue":"23","key":"10.1016\/j.pcad.2019.08.001_bb0050","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","article-title":"Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study","volume":"71","author":"Kosiborod","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"10166","key":"10.1016\/j.pcad.2019.08.001_bb0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet."},{"issue":"5","key":"10.1016\/j.pcad.2019.08.001_bb0060","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"24","key":"10.1016\/j.pcad.2019.08.001_bb0065","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2019.08.001_bb0070","unstructured":"Gerstein HC, Riddle MC, et.al. Once-weekly dulaglutide and major cardiovascular events \u2014 results of the REWIND trial. In: Association AD, ed. American Diabetes Association 79th scientific sessions. San Francisco, California: American Diabetes Association; 2019."},{"issue":"10157","key":"10.1016\/j.pcad.2019.08.001_bb0075","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet."},{"issue":"19","key":"10.1016\/j.pcad.2019.08.001_bb0080","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pcad.2019.08.001_bb0085","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pcad.2019.08.001_bb0090","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.pcad.2019.08.001_bb0095","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S2213-8587(18)30351-6","article-title":"GLP-1 receptor agonists and cardiovascular disease: drug-specific or class effects?","volume":"7","author":"Zweck","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pcad.2019.08.001_bb0100","doi-asserted-by":"crossref","unstructured":"Gunawan F, Partridge C, Kosiborod M, Inzucchi SE. Cardiologist vs. Endocrinologist Encounters in Patients with T2D and CVD: Potential Implications for Glucose-Lowering Therapy Use and Education. J Am Coll Cardiol. 2019;In Press - June 2019.","DOI":"10.1210\/js.2019-SUN-149"},{"issue":"15","key":"10.1016\/j.pcad.2019.08.001_bb0105","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1177\/2047487317729252","article-title":"Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR(R) research to practice project","volume":"24","author":"Arnold","year":"2017","journal-title":"Eur J Prev Cardiol"},{"issue":"25","key":"10.1016\/j.pcad.2019.08.001_bb0110","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1016\/j.jacc.2018.08.2202","article-title":"Prescriber patterns of SGLT2i after expansions of U.S. Food and Drug Administration labeling","volume":"72","author":"Vaduganathan","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2019.08.001_bb0115","doi-asserted-by":"crossref","unstructured":"American Diabetes A. Standards of Medical Care in Diabetes-2019 abridged for primary care providers. Clin Diabetes 2019;37(1):11\u201334.","DOI":"10.2337\/cd18-0105"},{"issue":"12","key":"10.1016\/j.pcad.2019.08.001_bb0120","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of Hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcad.2019.08.001_bb0125","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on Clinical Practice Guidelines Circulation 2019."},{"issue":"suppl 1","key":"10.1016\/j.pcad.2019.08.001_bb0130","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.2337\/dc18-S009","article-title":"9. Cardiovascular disease and risk management: standards of medical Care in Diabetes-2018","volume":"41","author":"American","year":"2018","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.1016\/j.pcad.2019.08.001_bb0135","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.2337\/dc19-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019","volume":"42","author":"American","year":"2019","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.pcad.2019.08.001_bb0140","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52","author":"Control","year":"2009","journal-title":"Diabetologia."},{"issue":"24","key":"10.1016\/j.pcad.2019.08.001_bb0145","first-page":"3200","article-title":"2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease","volume":"72","author":"Das","year":"2018","journal-title":"a report of the american college of cardiology task force on expert consensus decision pathways J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2019.08.001_bb0150","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.pcad.2017.09.001","article-title":"Insulin therapy increases cardiovascular risk in type 2 diabetes","volume":"60","author":"Herman","year":"2017","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.pcad.2019.08.001_bb0155","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCULATIONAHA.117.022680","article-title":"Are we ready to Bell the cat? A call for cardiologists to embrace glucose-lowering therapies proven to improve cardiovascular outcomes","volume":"138","author":"Nassif","year":"2018","journal-title":"Circulation."},{"issue":"1","key":"10.1016\/j.pcad.2019.08.001_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022577","article-title":"Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis","volume":"9","author":"Donnan","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.pcad.2019.08.001_bb0165","unstructured":"Research MFfMEa. Mayo Clinic History & Heritage - Quotations from the Doctors Mayo - http:\/\/history.mayoclinic.org\/toolkit\/quotations\/the-doctors-mayo.php. In: Research MFfMEa, ed. Mayo Clinic: Mayo Clinic; 2019."}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062019301033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062019301033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:16:28Z","timestamp":1758500188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062019301033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0033062019301033"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2019.08.001","relation":{},"ISSN":["0033-0620"],"issn-type":[{"type":"print","value":"0033-0620"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2019.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}